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HLA-G is a non-classical class I HLA molecule associated with suppression of immune responses 
during infection. We investigated HLA-G 3’ UTR genetic polymorphisms and HLA-G protein 
expression in HIV-1 high risk seronegative (HRSN) as well as infected individuals (HIV-1+). 
DNA samples from The Amsterdam Cohort Studies (ACS), comprising HIV-1+ MSM (Men who 
have Sex with Men) and IDU (Intravenous Drug Users), together with HRSN individuals were 
analysed for HLA-G 3’ UTR (untranslated region) genotypes and serum soluble HLA-G (sHLA-
G) plasma levels. HLA-G 3’ UTR haplotypes were determined through PCR amplification and 
subsequent DNA sequence analysis from the HIV-1 groups. sHLA-G concentrations were assayed 
through ELISA. Flow cytometry and real-time PCR technologies were used to identify whether 
leucocytes from healthy controls stimulated with HIV-1 pseudo-typed virus particles modulated 
HLA-G protein or mRNA expression levels, respectively. HLA-G 3’ UTR genetic polymorphisms 
within MSM and IDU HIV-1+ individuals were found to be similar to healthy controls whilst 
HRSN subjects showed a significantly higher proportion of specific 3’ UTR alleles previously 
associated with low levels of HLA-G expression: 3010C, 3027A, 3035T, 3142G and 14bpI 
(P<0.01) and haplotypes associated with lower levels of expression, UTR2, 5 & 7, were 
significantly better represented in the HRSN group (p= 0.0217). No differences were found in 
sHLA-G expression between the variant HIV-1+ groups or controls or between individuals 
carrying variant HLA-G 3’ UTR genotypes. Exposure of leucocytes to HIV-1 pseudo-typed viral 
particles had no effect on modulating HLA-G protein or mRNA expression. These results indicate 
that HLA-G 3’ UTR genetic polymorphisms linked with low HLA-G protein expression associate 
with protection against HIV-1 transmission in the ACS. 





Human Immunodeficiency Virus type 1 (HIV-1) is a serious global health issue with 
approximately 2 million new infections reported annually. In 2014, an estimated 1.2 million people 
died from acquired immune deficiency syndrome (AIDS) or AIDS-related illnesses resulting from 
HIV-1 infections [17,18]. Both men who have sex with men (MSM) and injecting drug users (IDU) 
are at high risk for HIV-1 acquisition and continue to pose challenges for HIV-1 prevention. MSM 
comprise one of the highest risk groups for HIV-1 infection worldwide [21].  
HLA-G is a non-classical class I HLA molecule typically expressed on extravillous 
cytotrophoblasts and in low levels on some leucocyte subsets [36]. However, in addition to its 
protective role in maintenance of pregnancy, it can also be involved in the evasion of immune 
responses against some infectious diseases or malignancies [39]. During viral infection, viruses 
can modulate the nonclassical HLA class I antigen HLA-G via diverse strategies such as disrupting 
immune competent cell recognition. HLA-G cell surface expression was found to be significantly 
induced in H1N1 infection when compared to non-infected controls, suggesting that elevated cell 
surface expression may favour virus evasion from host immune responses [10]. Differences in 
HLA-G surface expression on monocytes, plasma soluble HLA-G (sHLA-G), IL-10 and IL-6 
levels have been linked with Enterovirus 71 infection [56].  Similarly, HLA-G expression has been 
reported on hepatocytes and biliary epithelial cells within livers of chronic hepatitis C patients [3]. 
Taken together, this suggests that viral infections can induce HLA-G expression, which could be 
a mechanism enabling viruses to subvert host immune defences. 
In the context of HIV-1 infection, up-regulation of HLA-G cell surface expression on monocytes 
and on some T lymphocytes in HIV-1 positive individuals, irrespective of receiving antiretroviral 
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therapy (ART) was reported [9,29]. Increased expression of HLA-G at the fetomaternal interface 
was also noted in conjunction with HIV-1 infection [37]. Conversely, there are reports of ART 
inducing HLA-G expression on monocytes (12) and of HIV-1 downregulating HLA-G expression 
[14]. Furthermore, patients with the HLA-G*0501N allele, which does not encode for a functional 
HLA-G protein, were reported to be more resistant to HIV-1 infection [24,35]. Therefore, 
understanding the relationship between HLA-G expression and HIV-1 infection is important not 
only to identify and develop new effective drug therapies and vaccines against HIV-1 but also to 
improve diagnostic predictions [17]. 
In healthy individuals, levels of serum sHLA-G may increase as a result of physiological or 
pathological conditions, such as pregnancy, acute rejection episodes after organ transplantation, 
autoimmune diseases and some cancers. Interestingly, sHLA-G serum levels are elevated during 
some viral infections, including hepatitis B [47] and hepatitis C [54], influenza [10], 
cytomegalovirus [43], and HIV-1. Previously, the serum levels of sHLA-G were reported to be 
significantly elevated in HIV-infected subjects, and this was observed to influence disease 
progression and development of AIDS in addition to modulating the virologic and immunologic 
response to ART [18]. Several reports have linked sHLA-G levels to HIV-1 infection and virus 
susceptibility [15,20,23,25,40,41,49], with levels decreasing following initiation of ART [40,41].  
Unlike classical class I MHC molecules, HLA-G has limited coding region genetic 
polymorphisms. However, there is a 3’ untranslated region (UTR) dimorphism of HLA-G 
dependent upon deletion or insertion of a 14bp sequence which affects levels of HLA-G expression 
[49]. This and two further 3’UTR dimorphic sites, +3142C/G and +3187G/A have been suggested 
to be associated with HLA-G mRNA expression regulation with the 14bp deletion, 3142C and 
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3187G alleles being associated with increased expression [22,52,55]. To date, 44 haplotypes of the 
HLA-G 3′ untranslated region have been identified which contain eight variable sites. UTRs 1-7 
are the most frequent 3’UTR haplotypes, accounting for more than 96% of all the reported 
haplotypes worldwide [6,31,34], although further rarer haplotype have been identified [31]. UTR1 
contains all of the alleles associated with high levels of HLA-G expression whereas UTR7 
possesses all alleles associated with low levels of expression [8]. 
The aim here was to investigate the association of HLA-G genetic polymorphisms and expression 
levels between different clinical groups (HRSN versus HIV-1+) within the Amsterdam Cohorts 
Studies (ACS).  
Materials and Methods  
HIV patients and healthy controls 
DNA and plasma samples from time of diagnosis from various HIV-1 groups within the 
Amsterdam Cohort Studies (ACS) and healthy uninfected control individuals were utilised [12]. 
Further uninfected donors were obtained from the Institute of Infection and Global Health, 
University of Liverpool for HLA-G in vitro expression analysis. This study has been conducted in 
accordance with the ethical principles set out in the declaration of Helsinki and was approved by 
the institutional review board of the Amsterdam University Medical Centers (location Academic 
Medical Center). Written informed consent was obtained from all participants. 
 
HLA-G 3’UTR genetic polymorphism characterisation 
DNA samples from individuals within the different HIV-1 groupings and healthy controls were 
PCR amplified, sequenced and analysed for HLA-G genetic polymorphisms. Primers were 
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designed via free commercial software (OligoPerfect™ Designer, Thermo Fisher Scientific Inc. 
Web Tools). DNA was amplified with a set of two primers spanning the 3’UTR: 5′-GTG ATG 
GGC TGT TTA AAG TGT CAC C-3′, 5′-GGA AGG AAT GCA GTT CAG CAT GA-3′ (Sigma 
Aldrich).  PCR reactions were carried out with standard reagents using a thermos-cycler (Techne 
Thermal Cycler, Keison International Ltd. UK) with the programme set as follows: Initial 
denaturation at 94o C for 5min, followed by 30 cycles of denaturation at 94° C for 30s, annealing 
at 64° C for 45s, extension for 60s at 72° C and final extension at 72° C for 10 min.  
All the cleaned purified PCR products were sent off for Sanger sequencing using an ABI Big Dye 
sequencer (Source Biosciences Inc. UK). The reverse primer (3’ 
ACACGTGTACTGTGGAAAGTT ’5) was utilized for sequencing the DNA samples using the 
amplification process above. The results were reported electronically and the data were accessed 
with commercial software to manipulate and organize the data. 
The sequences obtained were analysed manually for specific SNPs by observing the 14 bp 
INS/DEL (rs1704), +3003 C/T (rs1707), +3010 C/G (rs1710), +3027 A/C (rs17179101), +3035 
C/T (rs17179108), +3142 C/G (rs1063320), +3187 A/G (rs9380142) and +3196 C/G (rs1610696) 
polymorphic sites, which were individually annotated according to previous reports [22,49]. 
Haplotypes and genotypes were assigned and named, including for homozygous and heterozygous 
individuals. 
Measuring sHLA-G plasma expression levels 
A BioVendor (Oxford Biosystems Ltd. UK) sHLA-G ELISA kit was used for the detection of 
soluble forms of human leucocyte antigen-G (sHLA-G) in archived frozen serum samples from 
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patients and healthy subjects. The assay was performed according to the manufacturer’s 
instructions. The reagents were prepared fresh at the time of assay and all reagents were brought 
to RT prior to use. 
Peripheral Blood Mononuclear Cell (PBMC) isolation and stimulation with 
HIV-1 Env pseudo-typed virus particles 
HIV-1 pseudo-typed virus particles were generated composed of HIV-1 structural proteins and 
expressing an HIV-1 CXCR4 envelope (Env) gp120/41 glycoprotein (CXCR4 tropic - LAI). We 
elected to utilise a CXCR4 using Env protein of HIV-1 as this is expressed at higher levels on CD4 
lymphocytes isolated from blood and under the assumption that both receptors are likely to 
stimulate in a similar manner. This is a chimeric construct in which two plasmids (p8.19, a 
construct containing gag-pol and pCSFLW, a construct with firefly luc under the control of the 
CMV promoter) were used as separate viral backbone vectors (1000ng and 1500ng respectively) 
in conjunction with a plasmid expressing HIV-1 Env LAI (900ng). 293T cells and PEI were used 
for plasmid transfection and media was changed 12-16 hours post transfection with viral stocks 
harvested 48 hrs later. The harvested supernatant was added to peripheral blood mononuclear cells 
(PBMC) from healthy subjects and the supernatant containing the virus was taken. Lastly, the 
supernatants were harvested to different production volumes depending on experimental need. 
PBMCs, prepared from healthy subjects by Ficoll density gradient separation, at a concentration 
of 1 x 106/ml were cultured with and without the HIV-1 LAI construct for 7 days in growth 
medium. Previous studies using CMV antigen stimulation had shown that HLA-G expression 
levels were shown to be modulated at day 7 post-exposure [2].  
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HLA-G mRNA expression levels determined through real-time PCR analysis 
RNA was extracted from stimulated and unstimulated PBMC and converted into cDNA using a 
high capacity cDNA reverse transcription kit (Applied Biosystems). qPCR was then carried out 
using a TaqMan® probe covering exons 5 and 6 (Assay ID: Hs00365950_g1, Applied Biosystems 
Inc. USA). The master mix (TaqMan® Universal Master Mix II, with UNG, Applied Biosystems) 
and the control positive housekeeping gene was used as a control (Assay ID: Hs01087168_m1, 
Applied Biosystems). Assays were carried out in duplicate using cDNA from 9 stimulation 
experiments. Differences in HLA-G expression between unstimulated and stimulated cultures 
were calculated using the ΔCT method.   
HLA-G cell surface expression levels determined through FACS analysis  
PBMCs were analysed at day 7 following culture with or without HIV-1 pseudo-typed virus 
particles were phenotyped with a panel of monoclonal antibodies (mAbs) corresponding to the 
antigens expressed by defined groups of cells: anti-CD3-FITC (IgG2a, no. 317306, Biolegend, 
London); anti-CD4-PE (IgG2b; no. 317410, Biolegend); anti-CD8-PE (IgG1; no. 9012-0087, 
eBioscience, Hatfield, UK); anti-CD19-PE (IgG1; no. 12-0198-42, eBioscience); anti-CD56-PE 
(IgG1, no. 12-0567-42,eBioscience); anti-HLA-G-APC (IgG1; clone MEM-G/9, no. A15708, Life 
Technologies, Paisley, UK); isotype control-PE (IgG2b; no. ab91532, AbCam, Cambridge, UK); 
isotype control-APC (IgG1; MG105, Life technologies). The Abs were selected on the basis of 
optimal matching of three fluorochromes (FITC, PE and APC) and 2- or 3-colour staining was 
performed using a BD Accuri C6 flow cytometer (BD Biosciences, Oxford). The main populations 
tested for changes in expression of HLA-G were CD4+, CD8+ and CD56+ T cells, B cells and NK 
cells. The mean proportions of each subset of lymphocytes expressing HLA-G were measured on 
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cells with or without culture with HIV-Env pseudo-typed virus particles for 7 days. Results were 
expressed as mean % HLA-G+ cells for different leucocyte subsets after subtracting background 
staining with an appropriate isotype control antibody. 
Statistical analysis 
Two-way ANOVA tests were used to analyse differences between genotype and allele frequencies 
between patient groups and controls. For analysis of soluble HLA-G levels, a Mann-Whitney U-
test was used as the data were not normally distributed. A value of P<0.05 was regarded as 
statistically significant.  
Results 
HLA-G 3′ UTR genotypes associated with HRSN status   
HLA-G 3’ UTR variant genotypes and haplotypes were determined for three defined clinical 
groups from the ACS along with controls (n=275 total): HIV-1+ MSM (n=133), HIV-1+ IDU 
(n=50), HRSN (n=32) along with control subjects (n=85). The alleles identified included: the eight 
previously reported HLA-G 3'UTR polymorphic sites [14-bp INS/DEL (rs1704), +3003 C/T 
(rs1707), +3010C/G (rs1710), +3027A/C (rs17179101), +3035 C/T (rs17179108), +3142 C/G 
(rs1063320), +3187 A/G (rs9380142) and +3196 C/G (rs1610696)] (25-27) with no other 
polymorphic sites observed in this region. The rationale was to identify whether frequencies of 
any of the high or low expressing alleles differed between patient groups, in particular, the HRSN 
group, which differed functionally from the other patient groups in response to virus exposure. 
The genotype frequencies of the eight HLA-G 3’UTR polymorphic sites observed within these 
patient groups were determined (Table 1). Upon performing a χ2 test to assess the occurrence of 
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these SNPs among the four designated patient groups, significant differences were found (Table 
1).  The data were also evaluated at the level of individual alleles (Table 2) and again significant 
differences were observed. Both the 3035T and 3010C alleles are associated with low levels of 
HLA-G expression and proportions of these were significantly greater in the HRSN group than the 
other HIV+ groups (MSM and IDU) as well as the control individuals (Table 2). Additionally, the 
3003C/T and 14bpI/D dimorphisms showed significant differences from the Hardy-Weinberg 
Equilibrium (Table 1). 
The HLA-G 3’ UTR haplotypes were then allocated for each patient group and healthy controls. Patients 
were allocated into the seven major haplotypes UTR1-7 (27). Based upon the alleles associated with high 
or low levels of HLA-G expression, haplotypes were allocated into one of three groups, potentially giving 
high (UTR 1), intermediate (UTRs 3, 4 & 6) or low levels of HLA-G expression (UTRs 2, 5 & 7). When 
haplotype groups for each patient group and controls were analysed, MSM and IDU groups were similar 
to controls but there were significantly higher proportions of low expressing haplotypes in the HRSN 
group, along with lower proportions of the high expressing haplotype UTR 1 (Figure 1).          
 
Serum sHLA-G levels do not differ between HIV+, HRSN and control 
individuals 
As a measure of HLA-G expression, sHLA-G serum levels were assayed, where sufficient sample 
was available, in HIV-1 groups [HIV+ (n=27) and HRSN (n=20)] and compared to healthy control 
subjects (n=20). Control sera provided a mean level of 35.5+/-32 u/ml, MSM gave 100+/-69 u/ml 
(n=20) and HRSN gave 116.1+/-79 u/ml (n=20). When compared no significant differences 
between sHLA-G levels between the HIV-1 groups (HIV+ and HRSN) or with controls were found 
(Mann-Whitney U-test; P>0.05). 
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HLA-G cell-surface expression does not change on immune cells when exposed 
to HIV-1 in vitro  
Since HLA-G 3’ UTR genetic polymorphisms associate with HIV-1 HRSN individuals, which are 
known to be linked to lower HLA-G expression, we aimed to identify whether exposure to virus 
results in lower HLA-G expression. We developed an assay where PBMC from healthy subjects 
were exposed to a high concentration of infectious but non-replicative competent HIV-1. The 
reasoning being that HRSN individuals have previously been exposed to either infectious HIV-1, 
defective viral particles or viral antigens at mucosal surfaces. We utilised a pseudo-typed virus 
system where HIV-1 backbone plasmids are co-transfected into a producer cell-line along with a 
plasmid expressing the HIV-1 LAI Env protein (CXCR4 utilising). This virus undergoes entry and 
integration but cannot subsequently replicate. PBMC from a panel of 11 healthy subjects 
independent of their UTR genotype were stimulated for 7 days in vitro with the HIV-1 LAI Env 
expressing pseudo-typed virus particles and where unstimulated cells served as a control. Different 
leucocyte populations were assessed for changes in HLA-G cell-surface expression by flow 
cytometry.   
Representative scatter plots are shown (Error! Reference source not found.2) and comparisons 
of the proportions of HLA-G+ cells on various cellular subsets stimulated with HIV-1 pseudo-
typed virus were made. Slight increases in the proportions of different leucocyte subpopulations 
expressing HLA-G following stimulation were observed. CD3+CD4+ lymphocytes were revealed 
to have the highest increase in proportion of HLA-G expressing cells, followed by CD3+CD8+ 
cells, followed by CD19+ cells, although all differences were <10% and none of them were 
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statistically significant (Fig. 2). The remaining subsets of PBMC showed no differences between 
stimulated and unstimulated cells in all of the 11 subjects.  
HLA-G mRNA expression levels were measured using real-time PCR and utilising mRNA 
isolated from PBMCs that had been stimulated with HIV-1 LAI pseudo-typed virus particles and 
compared to un-stimulated cells. The ΔCT values using an HLA-G probe for unstimulated and 
stimulated cells were 39.88 and 40.59 respectively (n=9 subjects), but these differences were not 
statistically significant (data not shown). 
Discussion 
HIV-1 infection and viral escape processes have been extensively studied [17]. Although an 
apparently appropriate immune response is initially induced by HIV-1 it typically evades the 
immune responses mounted [4]. Several studies have suggested that there is an increased 
expression of HLA-G after HIV-1 infection and that the immunomodulatory molecule HLA-G is 
capable of suppressing immune responses, although the real involvement of this molecule in virus 
infection and immune induction remain elusive [50]. In the present study we investigated the 
association between the 14 bp INS/DEL and other HLA-G 3’UTR gene polymorphisms with HIV-
1 infection. The evaluations were performed using different HIV-1 groupings from the ACS (MSM 
HIV-1+, IDU HIV-1+ and HRSN) and utilising regionally-matched controls. We observed an 
increased frequency of the genotypes related to low HLA-G expression (UTR-2, 5 and 7) in HRSN 
individuals in comparison to MSM HIV-1+, IDU HIV-1+ or healthy uninfected individuals. Taken 
together this suggests that low HLA-G expression alleles may play a role in protecting against 
horizontal HIV-1 transmission. 
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Previous studies have linked HLA-G genotypic variation with susceptibility to HIV-1 [32,35,51] 
with low levels of expression being protective [35]. Investigations of the 14bp Ins/Del dimorphism 
have been inconclusive, with some studies identifying the insertion allele as protective against 
HIV-1 infection or vertical transmission [26,46], while others showed the deletion allele to be 
protective [13,16,34,44]. The suggestion has been made that the 14bp INS/DEL dimorphism is not 
directly related to HIV-1 susceptibility [1] and it has been proposed that genetic variations in levels 
of expression are more relevant to HIV-1 vertical transmission in view of the extensive expression 
of HLA-G at the maternofoetal interface [45].  Here we found no difference in the frequencies of 
UTR genotypes in individuals either infected via MSM or IDU transmission and no difference 
between these two groups and control individuals.   
The 14bp INS/DEL dimorphism is only one of several 3’ UTR polymorphisms and consideration 
of genetic variation across the whole region is more likely to give an indication of the potential 
levels of HLA-G expression. The HLA-G 3′UTR region has a number of binding sites for miRNAs 
and the C/G polymorphism at position +3142 is the putative binding site for at least three miRNAs: 
hsa-mir-148a, hsa-mir-148b, and hsa-mir152, and has been subsequently confirmed to be the 
binding site for mir152 and it is noted that this binding reduces HLA-G expression [7,57]. 
However, the effect of this polymorphism in miRNA binding has been recently questioned as 
although mir-152 and mir-148a were found to bind to HLA-G 3′UTR and downregulate its mRNA, 
the C/G polymorphism at +3142 was found to have no effect on miRNA binding and efficacy [33]. 
The +3187G allele, associated with increased HLA-G expression and characteristic of the UTR1 
haplotype, was related to increased vertical transmission of HIV in a South African population 
[19]. Although the present results suggest that low-expressing HLA-G UTR haplotypes had a 
protective effect against horizontal HIV-1 transmission, we acknowledge that our findings are 
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restricted to patients from the Amsterdam Cohort, who are predominantly of Caucasian origin. 
Different findings have been reported for African populations [1,26] and further genetic studies 
are warranted in different populations.  
Serum levels of sHLA-G were reported to be significantly elevated in HIV-infected subjects [18] 
and sHLA-G has the ability to inhibit T lymphocyte proliferation and NK cell function [11,38,48]. 
sHLA-G could potentially interact with one of its ligands, KIR2DL4, found on NK cells and other 
PBMCs in order to moderate inflammatory mediator synthesis. In addition, the binding of sHLA-
G with ILT-4 on DCs can result in activating T reg cells which in turn participate in induction of 
tolerance favouring virus evasion [27]. There have also been reports of HLA-G-expressing 
regulatory T cells to be found in HIV-1 infected individuals [28,30] which are potential mediators 
of immune suppression of anti-HIV cellular immune responses. In the current study, sHLA-G 
serum levels did not differ significantly between the HIV-1 groups and controls. This may indicate 
that the sHLA-G protein is not the main mediator of immune suppression in HIV-1 infected 
individuals, but rather that cell plasma membrane-associated HLA-G is more important 
functionally. Alternatively, most sHLA-G may be taken up by cell surface HLA-G receptors and 
patterns of expression of the known receptors KIR2DL4, ILT-2 and ILT-4, may be relevant and 
may potentially vary in the presence of HIV infection. 
Changes in HLA-G expression were explored in response to HIV-1 LAI pseudo-typed virus in 
PBMC from healthy subjects. The proportions of HLA-G+ cells in various cellular populations 
harvested on Day 7 of culture with HIV Ag were compared to resting proportions of HLA-G+ 
cells. CD3+CD4+, CD3+CD8+ and CD3+CD56+ lymphocytes revealed slight but not statistically 
significant elevations of HLA-G expression on Day 7. Numerous studies were aimed at observing 
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changes in expression of HLA-G in the early stage of infection by HIV-1 and through disease 
progression. During HIV-1 infection the HLA-G1 isoform was found to be downregulated on 
macrophages [14] but in an earlier report both monocytes and T cells were found to express HLA-
G in HIV+ patients [29]. HLA-G+ CD8+ cytotoxic T cells were reported to be associated with 
protection against HIV-1 [53]. In the present experiments, not all HIV genes were present, only 
structural proteins as well as Env, therefore it remains possible that other HIV-1 protein (such as 
Nef) may be responsible for the modulation of HLA-G expression [42]. 
In conclusion, we identify that genetic polymorphisms within the 3’ UTR region (14 bp INS/DEL) 
of the HLA-G gene associate with HRSN individuals from the ACS and which differ from HIV-
1+ (MSM and IDU) or control individuals. The main finding is that an increased frequency of 
UTR genotypes related to low HLA-G expression (UTR-2, 5 and 7) were found in HRSN as 
compared to other patient groups and uninfected controls. This suggests that low expressing HLA-
G alleles may play a role in protecting against HIV-1 infection. It would be of great interest to 
extend these studies to other populations and to determine whether HLA-G expression in HIV-1 
infected individuals can be linked to other genetic polymorphisms and associate with disease 
outcome or treatment success.  
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Table 1. Genotype frequencies of HLA-G 3’ UTR genetic polymorphisms observed in the 
HIV-1 groups and healthy controls, Data analysed using χ2 tests. HWE = Hardy-Weinberg 
Equilibrium test.  
Group 














  P value HWE test 
p-value 
Genotype N Freq N Freq N Freq N Freq    
3003CC 2 0.01 4 0.03 0 0 2 0.04 <0.0001 0.006 
3003CT 23 0.27 78 0.59 4 0.13 12 0.24  
3003TT 60 0.71 51 0.38 28 0.88 36 0.72  
3010GG 25 0.29 20 0.15 3 0.09 15 0.3 <0.0001 0.951 
3010GC 43 0.51 100 0.75 16 0.5 21 0.42  
3010CC 17 0.19 13 0.1 13 0.41 14 0.28  
3027CC 74 0.87 128 0.96 26 0.81 48 0.96 0.007 0.802 
3027CA 11 0.11 5 0.04 6 0.19 2 0.04  
3027AA 0 0 0 0 0 0 0 0  
3035CC 65 0.76 121 0.91 19 0.59 47 0.94 <0.0001 0.871 
3035CT 18 0.21 12 0.09 12 0.38 3 0.06  
3035TT 2 0.01 0 0 1 0.03 0 0  
3142CC 22 0.26 26 0.2 4 0.13 14 0.28 <0.0001 0.446 
3142CG 46 0.54 100 0.75 16 0.5 23 0.46  
3142GG 16 0.19 7 0.05 12 0.38 13 0.26  
3187AA 35 0.41 55 0.41 17 0.53 23 0.46 0.825 0.339 
3187AG 42 0.49 71 0.53 13 0.41 23 0.46  
3187GG 7 0.08 7 0.05 2 0.06 4 0.08  
3196CC 40 0.47 36 0.27 13 0.41 21 0.42 0.003 0.945 
3196CG 36 0.42 91 0.68 14 0.44 23 0.46  
3196GG 9 0.09 6 0.05 5 0.16 6 0.12  
14bpII 16 0.18 6 0.05 11 0.34 7 0.14 <0.0001 0.006 
14bpDD 26 0.31 23 0.17 5 0.16 19 0.38  





Table 2. Allele frequencies of HLA-G 3’ UTR genetic polymorphisms observed  
in the HIV-1 groups and controls 
Group 












Allele N Freq N Freq N Freq N Freq  
3003C 27 0.16 86 0.32 4 0.06 16 0.16 <0.001** 
3003T 143 0.84 180 0.68 60 0.94 84 0.84 0.009* 
3010G 93 0.55 140 0.53 22 0.34 51 0.51 0.014* 
3010C 77 0.45 126 0.47 42 0.66 49 0.49 0.04* 
3027C 159 0.94 261 0.98 58 0.91 98 0.98 0.001* 
3027A 11 0.06 5 0.02 6 0.09 2 0.02 0.01* 
3035C 148 0.87 254 0.95 50 0.78 97 0.97 0.001* 
3035T 22 0.13 12 0.05 14 0.22 3 0.03 0.046* 
3142C 90 0.54 152 0.57 24 0.38 51 0.51 0.085 
3142G 78 0.46 114 0.43 40 0.63 49 0.49 0.008* 
3187A 113 0.66 181 0.68 47 0.73 69 0.69 0.408 
3187G 57 0.34 85 0.32 17 0.27 31 0.31 0.632 
3196C 116 0.68 163 0.61 40 0.63 65 0.65 0.098 
3196G 54 0.32 103 0.39 24 0.38 35 0.35 0.492 
14bp I 75 0.44 116 0.44 38 0.59 38 0.38 0.01* 
14bp D 95 0.56 150 0.56 26 0.41 62 0.62 0.125 
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Fig. 1 Haplotypes of the HLA-G UTRs in HIV-1 groups: MSM, IDU, HRSN and controls  
HLA-G 3’ UTR haplotypes were allocated into 3 groups, based upon potential levels of HLA-G 
expression (25). Comparison of the haplotypes defined for the groups showed that HRSN exhibited 
a significantly higher proportion of low expressers (UTR2/5/7) after performing a 2-way ANOVA; 
(**P=0.0217). 
Fig. 2 HLA-G expression by PBMC stimulated with or without HIV-1 pseudo-typed virus 
for 7 days  
Representative flow cytometry plots of staining of lymphocytes with anti HLA-G after 7 days of 
culture with or without LAI HIV-1 pseudo-typed virus. Three colour staining of the T cell helper 
subset for CD3, CD4 and HLA-G. CD8 T cells were stained for CD3, CD8 and HLA-G. Two 
colour staining of B lymphocytes for CD19 and HLA-G. Three colour staining of CD56+ T cells 
for CD3, CD56 and HLA-G.   
 
 
